Berenberg initiated coverage on 23andMe with a new price target
$ME
Biotechnology: Pharmaceutical Preparations
Health Care
Berenberg initiated coverage of 23andMe with a rating of Buy and set a new price target of $7.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/29/2022 | $7.00 | Buy | Berenberg |
| 9/22/2022 | $6.00 | Outperform | Cowen |
| 2/11/2022 | $14.00 → $11.00 | Outperform | Credit Suisse |
| 12/20/2021 | $13.00 → $9.00 | Neutral | Citigroup |
| 11/15/2021 | $12.00 → $13.00 | Buy → Neutral | Citigroup |
| 11/11/2021 | $13.00 → $14.00 | Outperform | Credit Suisse |
| 8/17/2021 | $13.00 | Outperform | Credit Suisse |
| 7/12/2021 | $14.00 | Buy | Citigroup |
Berenberg initiated coverage of 23andMe with a rating of Buy and set a new price target of $7.00
Cowen initiated coverage of 23andMe with a rating of Outperform and set a new price target of $6.00
Credit Suisse reiterated coverage of 23andMe Holding with a rating of Outperform and set a new price target of $11.00 from $14.00 previously
SAN FRANCISCO, March 26, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. ("23andMe" or the "Company") (NASDAQ:ME), a leading human genetics and biotechnology company, today announced that it has received approvals from the U.S. Bankruptcy Court for the Eastern District of Missouri (the "Court") for its "first day" motions related to 23andMe's voluntary Chapter 11 petitions filed March 23, 2025, including authorization to pay employee wages and benefits and compensate certain vendors and suppliers in the ordinary course for goods and services provided and to enter into the binding term sheet for a $35 million debtor-in-possession financing facility from JMB Capital Partners (the "DIP Facility"
Intends to use Proceedings to Conduct a Value-Maximizing Sale Process and Resolve Liabilities Company Expects to Continue Business Operations in the Ordinary Course During Proceedings; Secures Commitment for Approximately $35 Million in DIP Financing to Support Ongoing Operations No Changes to Customer Data Management and Access; Company Remains Committed to Transparency Around Customer Data Privacy; Any Buyer will be Required to Comply with Applicable Law with Respect to Treatment of Customer Data Company Announces Board and Leadership Changes to Support Restructuring and Sale Process SAN FRANCISCO, March 23, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. ("23andMe" or the "Company") (
SAN FRANCISCO, March 21, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics company with a mission to help people access, understand, and benefit from the human genome, today released a new report on the genetics of homocysteine levels for 23andMe+ Premium members, as well as a blood test for next steps in further understanding said levels for an additional fee. One of the top 23andMe customer requested reports, it informs users if they are at a higher likelihood of developing slightly elevated homocysteine levels along with actionable lifestyle factors that can reduce their chances. Homocysteine is an amino acid that plays a key role in important process
3 - 23andMe Holding Co. (0001804591) (Issuer)
3 - 23andMe Holding Co. (0001804591) (Issuer)
4 - 23andMe Holding Co. (0001804591) (Issuer)
8-K - 23andMe Holding Co. (0001804591) (Filer)
8-K - 23andMe Holding Co. (0001804591) (Filer)
10-Q - 23andMe Holding Co. (0001804591) (Filer)